Applying the evidence of what works from HIV-related stigma and discrimination in six settings to the COVID-19 response
This brief provide evidence-informed guidance to countries on the intersection of stigma related to HIV and COVID-19 in national responses.
Connecting global priorities: biodiversity and human health: a state of knowledge review
PLOS ONE | https://doi.org/10.1371/journal.pone.0196380 May 15, 2018
Offering additional pre-exposure prophylaxis (PrEP) choices has the potential to increase uptake and effective use of PrEP, and of HIV prevention overall, as it allows people to choose a method that they prefer.
In this guideline, WHO recommends an offering long-acting injectable lenacapavir (LEN...) as an additional HIV prevention choice, as part of combination HIV prevention approaches. LEN, administered twice a year as PrEP, has been shown to be highly effective at reducing the risk of HIV acquisition. In this guideline, WHO also recommends using HIV rapid diagnostic tests (RDTs) for individuals initiating or continuing long-acting injectable PrEP, such as LEN and long acting injectable cabotegravir (CAB-LA). Flexible HIV testing approaches are essential for ensuring that testing does not become a barrier to accessing or continuing PrEP, including long-acting injectable options.
more
Guidelines on lenacapavir for HIV prevention and testing strategies for long-acting injectable pre-exposure prophylaxis. Web Annex B
What you need to know about cancer and how to prevent it.